1	Cost-effectiveness of vector control strategies for supplementing mass drug
2	administration for eliminating lymphatic filariasis in India
3	
4	Short title: Cost-effectiveness of strategies for lymphatic filariasis elimination
5	
6	
7	Donald S. Shepard Ph.D. ¹
8	Aung K. Lwin M.D., M.S. ¹
9	Sunish I. Pulikkottil Ph.D. ^{2,3}
10	Mariapillai Kalimuthu M.Sc., M.Phil. ²
11	Natarajan Arunachalam Ph.D. ²
12	Brij K. Tyagi Ph.D. ^{2,4}
13	Graham B. White Ph.D. ⁵
14	
15	¹ Heller School for Social Policy and Management, MS035, Brandeis University,
16	Waltham, Massachusetts 02454-9110 USA
17	
18	² Indian Council on Medical Research (ICMR) Centre for Research in Medical
19	Entomology, Field Station, 4-Sarojini Street, Chinna Chokkikulam, Madurai 625 002,
20	Tamil Nadu, India
21	
22	³ Regional Medical Research Centre (ICMR), Port Blair 744103, Andaman & Nicobar
23	Islands, India
24	
25	⁴ Department of Zoology & Environment Science, Punjabi University,
26	Patiala, Punjab 147002, India
27	
28	⁵ Department of Entomology and Nematology, University of Florida, P.O. Box 110620,
29	Gainesville, Florida 32611-0620, U.S.A.
30	Company and the provide the provident of the second state of the s
31	Corresponding author: Donald S. Shepard, Heller School for Social Policy and
32	Management, MS035, Brandeis University, Waltham, Massachusetts 02454-9110 USA.
33	Tel: +1-617-584-6664, E-mail: shepard@brandeis.edu

It is made available under a CC-BY 4.0 International license .

35

Abstract

36	Background/Methodology: Despite progress using mass drug administration (MDA),
37	lymphatic filariasis (LF) remains a major public health issue in India. Vector control
38	(VC) is hypothesized as a potentially useful addition to MDA towards LF elimination. We
39	conducted cost-effectiveness analysis of MDA alone and augmented by VC single
40	(VCS) or integrated VC approaches (VCI). Data came from historical controls and a 3-
41	arm cluster randomized trial of 36 villages at risk of LF transmission in Tamil Nadu,
42	India. The arms were: MDA alone (the standard of care); VCS (MDA plus expanded
43	polystyrene beads for covering the water surface in wells and cesspits to suppress the
44	filariasis vector mosquito Culex quinquefasciatus), and VCI (VCS plus insecticidal
45	pyrethroid impregnated curtains over windows, doors, and eaves). Economic costs in
46	2010 US\$ combined government and community inputs from household to state levels.
47	Outcomes were controlled microfilaria prevalence (MfP) and antigen prevalence (AgP)
48	to conventional elimination targets (MfP<1% and AgP<2%) from 2010 to 2013, and
49	disability adjusted life years (DALYs) averted.

Principal Findings: The estimated annual economic cost per resident was US\$0.53 for MDA alone, US\$1.02 for VCS, and US\$1.83 for VCI. With MDA offered in all arms, all reduced LF prevalence substantially and significantly from 2010 to 2013. MDA proved highly cost effective at \$112 per DALY, a very small (8%) share of India's then per capita GDP. Progress towards elimination was comparable across all three study arms.

It is made available under a CC-BY 4.0 International license .

- 56 **Conclusions**: The well-functioning MDA was effective and very cost-effective for
- ⁵⁷ eliminating LF, leaving little scope for further improvement. Supplementary VC
- 58 demonstrated no statistically significant additional benefit in this trial.

It is made available under a CC-BY 4.0 International license .

59

Authors' Summary

60	Lymphatic filariasis (LF) is one of the twenty neglected tropical diseases (NTDs) that
61	affect more than one billion people worldwide. As part of the effort toward global
62	elimination of LF, the Indian State of Tamil Nadu government has implemented mass
63	drug administration (MDA) repeatedly since 1996. Despite their efforts, LF had not yet
64	been eliminated. Although vector control (VC) is proposed to augment regular MDA to
65	help eliminate LF, little is known about the increased impact or costs. Our study
66	compares the costs of MDA alone to the combination of MDA with alternative VC
67	interventions. We calculated both program operating costs and costs to communities.
68	We found MDA to be very cost-effective for eliminating LF. Against low levels of LF
69	endemicity (\leq 10%), the study had limited ability to detect further improvements and
70	found no significant incremental improvements from VC.
71	

It is made available under a CC-BY 4.0 International license .

72

Introduction

73	Among the neglected tropical diseases [1] prevalent in India, lymphatic filariasis
74	(LF) remains a major public health problem [2-5]. This chronic disease is characterized
75	by acute episodes of fever with painful lymph nodes (adenolymphangitis) and
76	progressive swelling of lower and/or upper limbs (lymphoedema) and testes
77	(hydrocele), resulting in loss of labor and depleting the quality of life for those infected
78	[6]. The latest data show substantial reductions in LF prevalence in most endemic
79	countries and LF elimination from 20 countries [7], but still the persistence of a major
80	global problem [8]. To prevent this debilitating disease in India, the country launched the
81	National Filaria Control Programme in 1955 [9]. Control of LF is based on mass drug
82	administration (MDA), where local workers give an annual dose of preventive medicines
83	to all residents of the target area.

The Indian State of Tamil Nadu, with a strong public health infrastructure, began 84 MDA in 1996 and gradually extended the program to cover all LF endemic districts [4]. 85 Initially the MDA program administered a single dose of diethylcarbamazine (DEC) to 86 each eligible person; starting in 2000, the program administered DEC plus albendazole 87 annually to the whole population of districts (implementation units) where LF was 88 endemic [10, 11]. In 2015, MDA covered 255 districts of 21 states and territories in 89 India where 630 million people are at risk of LF transmission [2]. However, even after 5 90 rounds of MDA with both drugs, pockets of LF infection persist [12], attributed to 91 inadequate MDA coverage, likely due to non-compliance with timely ingestion of the 92 free antifilarial drugs [13, 14]. 93

It is made available under a CC-BY 4.0 International license .

LF is mostly caused by the nematode worm *Wuchereria bancrofti*, transmitted in 94 95 India by vector *Culex quinquefasciatus* mosquitoes [15, 16] which develop in polluted 96 water, such as water drained into cesspits and sewers [17]. Implementing vector control (VC) programs to interrupt filariasis transmission is considered a potentially beneficial 97 supplement to MDA programs [18, 19], perhaps essential towards the elimination of LF 98 [20, 21]. Epidemiological evidence of the benefit from supplementary VC [22, 23] 99 reported that two annual rounds of MDA augmented by VC with expanded polystyrene 100 beads (EPB) and larvivorous fishes to control *Culex* aquatic stages reduced both the 101 102 annual transmission potential and the transmission intensity index of LF to zero in Tamil Nadu villages [24]. A cost-effectiveness study determined that adding VC with two 103 annual rounds of MDA decreased the prevalence of microfilaremia by 1% with an added 104 cost of US\$0.85 per person annually [25]. 105

In 2009, the Indian Council for Medical Research Centre for Research in Medical 106 Entomology (CRME) commenced this prospective randomized trial in Tamil Nadu to 107 examine the effects of specific VC interventions for augmenting MDA, compared with 108 the regular MDA program alone. Both VC and MDA strengthened social cohesion by 109 110 combining community-based initiatives, multiple levels of Indian government, and global partners. The results showed that all of the interventions were associated with 111 significant reductions in LF [26, 27], highlighting the need for further analysis to clarify 112 113 the best strategy. As LF has persisted both globally and specifically in India, the global health community, donors, and national governments have continued searching for 114 affordable interventions to eliminate LF. Emerging problems, such as controlling the 115 COVID-19 pandemic, compete for global public health resources. Cost constraints 116

It is made available under a CC-BY 4.0 International license .

affect all levels--local communities, national governments, and global institutions. LF,
 one of the most neglected diseases, and COVID-19, currently one of the most salient
 global problems, both illustrate the challenges of implementing technologies with
 available resources.

121 Despite decades of effort, LF continues to affect the most marginalized 122 communities. It is not clear whether the existing strategy, MDA, will be sufficient to eliminate LF as a public health problem. To our knowledge, Sunish et al. [26, 27] 123 conducted the only controlled study of effectiveness of augmenting MDA with VC. 124 Sound policies depend not only on effectiveness, but also on costs. To determine the 125 best use of available resources, this cost-effectiveness study assessed the costs of the 126 comparative interventions of Sunish et al. [26, 27] and built on previous research by 127 CRME [22, 23, 28]. Our study measures the costs and effectiveness of MDA, assesses 128 the incremental costs of VC interventions, and computes the incremental cost-129 130 effectiveness ratio of adding VC interventions compared to regular MDA alone. With its rigorous assessment of costs and outcomes, we feel that this study offers key 131 information about future LF control. 132

133

134

Methods

135 Setting

The State of Tamil Nadu had a population of 72 million persons in 2011 [29]. Lymphatic filariasis was endemic in at least 20 of its 33 districts [30]. The State Health Department funds health services in all districts. In 2008-09, the public system contained 42 health unit districts (HUDs) which supervised 1,421 primary health care

It is made available under a CC-BY 4.0 International license .

140 (PHC) units in Tamil Nadu, with each PHC serving about 30,000 residents [31]. This 141 cluster randomized trial collected data from 2010 to 2013 in Kallakurichi Health Unit 142 District [32], which had a population of 3.5 million residents and 36 PHC units. The CRME, with headquarters in Madurai, Tamil Nadu, opened a field station in the 143 144 Tirukoilur block of the Kallakurichi Health Unit of Villupurum [22]. The entomological team selected 36 villages as study sites based on their high risk of LF (Figure 1). With a 145 combined population of 43,000 people, they were under three PHC units in the 146 Tirukoilur block: Ariyur, Edaiyur and T.Kunnathur. Altogether, these three PHCs 147 provided health care for about 150,000 people. 148

The CRME randomly assigned 12 villages to each of the three study conditions. 149 The allocation was balanced exactly by LF microfilaremia baseline prevalence (MfP) 150 and ecological circumstances for mosquitoes: 3 villages with MfP<1%, 3 villages with 151 MfP 1-2%, and 6 villages with MfP>2%; and agreed closely in distribution by condition 152 within each PHC block. The World Health Organization [33] defined the eligibility of 153 communities for MDA treatment as the prevalence of filarial parasites (MfP) or antigen 154 of more than 1%. While the population of villages varied [mean (M) = 1914, standard 155 156 deviation (SD) =8971, all villages included in this study were eligible for treatment (M = 85%, SD = 9%) with the WHO's recommended two-drug regimen of DEC and 157 albendazole [34]. 158

159 Kallakurichi Health Unit District lies in northern Tamil Nadu, 40 to 80 kilometers 160 inland from Puducherry on the Indian east coast. The general climate in the region is 161 hot and dry, with moderate rainfall from September to December [35]. The majority of 162 villagers are landless laborers who earn their living from agriculture and livestock [28].

It is made available under a CC-BY 4.0 International license .

For community management and administration, village committees are led by elected village presidents. Government health personnel contact with villagers relies on the village health nurse, who manages a PHC satellite unit called a sub-center, that serves approximately 5,000 inhabitants in two to three villages [36].

Prior to the study, no systematic VC operations had been routinely implemented 167 in the study area. Villages have abandoned wells, since tap water standpipes have 168 been installed. Sanitation involves pit latrines. The majority of houses lack effective 169 barriers to insects, allowing endophilic mosquitoes easy access into the interior of 170 dwellings and thus are able to bite residents inside. Due to the region's hot and humid 171 weather, villagers mostly prefer not to use bed nets for the prevention of mosquito bites, 172 because they reduce ventilation. Traditionally, water used for showering and cleaning 173 utensils is disposed of in soakaway pits and wet ditches, which readily serve as 174 breeding sites for *Culex* mosquitoes. 175

176

177 Study design

The State Health Department (SHD) of Tamil Nadu implements MDA almost 178 annually with tablets of DEC, procured from local manufacturers in India [4], plus 179 albendazole donated by the pharmaceutical company GlaxoSmithKline [37], following 180 procedures and dosage regimens recommended by the Global Program to Eliminate 181 Lymphatic Filariasis [38]. In the study area, the SHD organized the local program to 182 eliminate lymphatic filariasis through five management levels: the Tamil Nadu SHD. 183 184 Kallakurichi Health Unit District, primary health centers (PHC), sub-centers, and village delivery units of filariasis prevention assistants. 185

It is made available under a CC-BY 4.0 International license .

186 Drugs for MDA were transported by the SHD to its HUDs, then distributed to their 187 block level PHCs. Village health nurses of sub-centers carried drugs from the block 188 level PHCs to their villages and supervised the most peripheral workers of the delivery chain, the filariasis prevention assistants, who were volunteers. Recruited from village 189 190 communities, filariasis prevention assistants directly delivered drugs to the households and observed residents swallowing their tablets. In each annual MDA campaign, one 191 day is scheduled for filariasis prevention assistants to deliver to households, and two 192 days are scheduled for tracing and providing treatment of those missed on the 193 194 preceding day.

Multiple levels of management are required to coordinate delivery of the MDA tablets to residents in the 36 villages investigated. Upper health management levels were involved in more extensive distribution efforts to villages across the State that were not part of this study's population, although the cost shares of higher-level centers were pro-rated based on their total population coverages. Table 1 shows how a village is integrated into the combined State efforts of all health management levels and associated responsibilities.

202

203 <Insert Table 1 about here>

204

The VC intervention delivery system for this CRME research study was less hierarchical than that of the National MDA program administered by the state. Major

It is made available under a CC-BY 4.0 International license .

207 activities of added VC interventions were carried out solely by the CRME team, in close 208 collaboration with Ariyur block PHC staff members, and other field-level government 209 staff for some part of the monitoring and evaluation efforts. CRME recruited volunteers 210 from villages, trained and motivated them for 'Vector Control through Community' [27] to 211 facilitate VC activities by community members. While the two higher administrative 212 levels (SHD and HUD) did not perform VC operations during the study, they would manage these activities should the VC programs be adopted nationwide. To make 213 comparisons of interventions more realistic for future purposes, we simulated costs of 214 senior management level efforts in addition to actual efforts of CRME and the 215 contributions from its associated government management centers. 216

217

218 **Description of treatment conditions**

The MDA program (intended annually but subject to dates of convenience for 219 220 administrative and logistical reasons) administered anti-filarial DEC and anthelminthic albendazole to target at-risk communities. DEC, by immune mechanisms still largely 221 undefined, causes rapid clearance and destruction of the filarial larvae (microfilariae) 222 circulating in the blood as well as the slower, progressive death of the adult filarial 223 worms. Albendazole is a broad-spectrum anthelminthic drug that principally affects the 224 adult worms, thereby inhibiting the production of microfilariae and suppressing 225 transmission of LF. 226

Two interventions were applied for integrated control of the LF vector *Culex quinquefasciatus*. Against the developing stages of *Culex*, a floating layer of expanded polystyrene beads (EPB) was applied at rates of 350–400 g/m² water surface area to

It is made available under a CC-BY 4.0 International license .

230	the main breeding sites (cesspits and wells) to deter mosquito oviposition and
231	asphyxiate larvae and pupae by keeping them submerged [39]. Against the adult Culex
232	mosquitoes, pyrethroid impregnated curtains (PIC) were installed to mosquito landing
233	sites around houses (doors, eaves, and windows) to kill adult insects by contact with
234	insecticidal pyrethroid [40].
235	Polystyrene resin granules (Shri Sakthi Insulations, Chennai, TN) were boiled to
236	produce the expanded lightweight, ~2mm diameter EPB [41]. To facilitate the placement
237	and retention of EPB in mosquito breeding sites, it was necessary to modify cesspit
238	frames and unused wells to prevent water overflowing, which would flush away the
239	EPBs. Therefore, cesspits were lined with brick walls, and unused wells were cleaned
240	and covered by a custom-made metal mesh screen in a wooden frame.
241	The PIC intervention required measurement of the doors, windows and eaves for
242	tailoring curtains to fit these spaces. Curtain materials were made of white woven
243	ventilated polypropylene (VIRGO Polymer India Ltd., Kanchipuram, TN
244	https://virgopolymer.com/fibc/ventilated-fibc) impregnated with deltamethrin insecticide
245	(2.5% SC, Chemet Wets & Flows Pvt. Ltd., Ahmedabad, Gujarat) by soaking and drying
246	in the shade to achieve approximately 25mg ai/m ² dosage, before cutting, sewing
247	borders and installation by hanging with nails. Installed curtains had to be re-treated by
248	spraying every six months to sustain insecticidal efficacy (validated by CRME
249	bioassays). CRME implemented both interventions in their assigned villages from March
250	to June 2010.

251

252 Collection of cost data

It is made available under a CC-BY 4.0 International license .

253 For both MDA and VC programs, personnel costs were calculated using time 254 allocation surveys, salary and wage records, reports, and narrative interviews with paid 255 and volunteer workers. Reports were used to allocate SHD staff time, while time 256 allocation surveys were completed by managers and some community leaders for all 257 levels below the SHD. The salary of each full-time worker and the opportunity cost of each volunteer were collected from administrative records at the SHD, HUD, three 258 BLPHCs, the CRME headquarters and its field station. Narrative interviews clarified 259 implementation procedures and tasks of health workers and community volunteers. 260 Validated costs of major activities of MDA and VC for each management level of Tamil 261 Nadu's health system were entered into a customized Excel spreadsheet (Microsoft 262 263 Corp., Redmond, Washington) cost analysis tool developed to combine the costs of MDA and VC activities from different management levels. 264 Both MDA and VC involved considerable efforts by community members. 265

Current MDA programs engaged full community mobilization efforts once a year, while VC programs required full community mobilization in the initial year and regular maintenance by villagers in subsequent years. Community mobilization efforts for introducing VC were underway in the study villages at the time of the research team's visit to India. For a narrative understanding, Brandeis investigators with CRME interpreters interviewed participants at every level from the SHD to households.

272 Non-personnel items consisted mainly of transportation costs (allocated costs of 273 vehicles and fuel) for all activities, drugs for MDA, polystyrene granules, cooking pots 274 and fire for EPB production, construction materials (bricks, cement, tools) for improving 275 cesspits, insecticide, curtains and tools for cutting and sewing them for PIC. We

It is made available under a CC-BY 4.0 International license .

collected information on non-personnel costs of MDA from administrative records from
the PHC, interviews with supervisors, and vector control program reports [42]. To
estimate economic costs of donated drugs, we asked informants for local retail prices
and validated these against the International Drug Price Indicator Guide, 2009 [43]. For
VC interventions, CRME documents and officials provided recorded expenditures on
non-personnel items. Authors communicated regularly with CRME Field Unit staff
(Supporting information S1 Figure and Supporting information S2 Figure).

283

284 Analysis of cost data

WHO and its international partners such as the United States Agency for International Development (USAID) adopted a 3-stage "roll-out package" [44] against NTDs, assuming that integration and scale-up of various programs to full-national scale is feasible [45]. Our analysis followed similar assumptions that various approaches to eliminating a single NTD can be integrated and scaled up by the national ministries.

In our current LF study, one arm applied only one intervention (regular MDA). 290 The other two arms used combined interventions: VCS combined MDA with EPB and 291 292 VCI combined MDA, EPB and PIC. We estimated the cost of each intervention separately and assumed that, for a combined program, we could add the components to 293 estimate the final costs of the integrated approaches. Our analysis of unit costs of each 294 295 intervention consists of three major steps: (1) estimating total recurrent costs (personnel and non-personnel) by management level, (2) annualizing capital costs, and (3) 296 297 calculating final unit costs per beneficiary.

It is made available under a CC-BY 4.0 International license .

298 Microsoft Excel was used to create two cost analysis tools: mass drug 299 administration cost analysis tool (MDA-CAT) and VC cost analysis tool (VC-CAT), which 300 were used to enter the data and perform cost analyses. Raw data from our data collection instruments provided estimates of aggregate costs of personnel activities and 301 302 non-personnel inputs. We categorized these costs by each management level, i.e., the State Health Department, intermediary management levels, and household groups. As 303 higher levels served populations of varying sizes beyond the study's 36 villages (Table 304 1), we converted the costs at each administrative level to their corresponding per capita 305 306 amounts, including the administrative costs of hiring personnel and procuring materials for VC and MDA. To compare yearly costs across the implementation strategies, we 307 308 amortized capital assets over their useful lives.

In contrast to the State-run annual MDA programs, the VC activities initiated 309 specifically for this study were managed by CRME and funded with donor support. 310 Community mobilization was most intense in the first year; project managers estimated 311 that only 15% of the staff's initial year efforts were necessary in subsequent years when 312 communities were presumed to be self-sufficient for continuing their VC efforts. While 313 MDA required the procurement and dissemination of drugs once a year, the lifetime of 314 installed VC materials varied. For example, EPB required yearly production and 315 316 reapplication, whereas PIC curtains were expected to last for three years, while insecticide spray on curtains needed to be reapplied every six-months. 317

Our analysis computed per capita costs based on the number of residents benefiting from each service. For MDA interventions, the combination of drugs served

It is made available under a CC-BY 4.0 International license .

one person. For PICs, the curtain benefited one household (average of five persons)
while one cesspit modification served 27 households (135 persons). Most cost data on
personnel activities and non-personnel inputs were initially collected in Indian rupees.
The project was planned, and many costs were incurred in 2010. We therefore
converted Indian rupees to US dollars based on the market exchange rate of 45.8
rupees per US dollar in early 2010 [46] and expressed all costs in 2010 US\$.

326

327 Analysis of impact

The CRME entomological team collected baseline data of parasitological 328 prevalence and entomological status before the intervention (February 2010) and 329 continued to collect yearly data on the post-intervention progress for three years. We 330 collected data on microfilaria prevalence (MfP) tested by microscopic examination of 331 night-time collection of blood smear samples and AgP using the 332 immunochromatography card test (ICT, BinaxNOW® Filariasis, Alere Inc., Portland, 333 Maine) for MfP and AgP, commonly used indicators to monitor progress towards LF 334 elimination [47-49]. 335

To evaluate the impact of the various control strategies, we first evaluated the impact of the reference strategy, MDA. As MDA is the standard treatment in India, there was on control area without MDA. Instead, we selected as the comparator the historical situation in 2010, as implementation of and compliance with MDA had traditionally been low [50]. We calculated the cumulative improvement from 2010 to 2013 in the share of villages reaching the benchmarks towards elimination of MfP and AgP as public health problems -- MfP<1% and AgP<2%. Dividing by 3 (for 3 years), we

then calculated the average annual improvement.

344 To evaluate the incremental improvement of VC over MDA, we performed logistic 345 regression analyses with these shares of villages controlled based on MfP<1% or AgP<2% as the dependent variable using Stata version 15 (StataCorp, College Station, 346 347 TX). The independent variables were the final year of intervention (year), the intervention (MDA alone, as the baseline level, VCS, and VCI), and interaction terms. 348 These interaction terms on MfP and AgP (intervention level x year) are the main 349 variables of interest, indicating the differential effectiveness of each combination of 350 interventions after controlling for baseline conditions and general trends. Finally, to 351 contextualize our findings we examined India's national prevalence of LF from 1990 352 through 2019, the latest data available. 353

354

355 Cost-effectiveness analysis

For assessing the cost-effectiveness of VC, we converted the average annual 356 improvements from VC by arm into disability adjusted life years (DALYs) averted per 357 1,000 population. As the first step, we needed the annual DALY burden per person 358 359 affected by LF. The one study of which we were aware reported an annual burden per case of 0.11 [51]. However, this relatively high value apparently reflected only 360 symptomatic persons, rather than the broader population of persons infected. To derive 361 an estimate for this broader population, we relied on the Global Burden of Disease 362 (GBD) study. Using the most recent year available (2019), we divided India's rate of 363 years lost to disability (58.96/100,000) due to LF by its prevalence (2.68%) [52], deriving 364 a burden of 0.022 DALYs per person affected. Finally, we divided the incremental cost 365

It is made available under a CC-BY 4.0 International license .

per 1,000 population by the incremental DALYs averted per 1,000 population to get the
 incremental cost-effectiveness ratios (ICER) by arm.

368

369

Results

370 Economic cost per person treated

Table 2 summarizes lifespans of the inputs and their target beneficiaries. Table 371 3 presents the ingredients costs (unit costs and quantities) of each component per 372 1,000 population at the village level. Table 4 presents the corresponding analysis at a 373 higher level (the block level). Table 5 expands the cost analysis to all levels of the 374 health care system. Table 5 shows that approximately 25% of the economic costs for 375 the MDA program (\$110.94 compared to \$533.55) were borne by the communities 376 served. From the community perspective, PIC was the costliest intervention, EPB was 377 intermediate, and MDA was least costly. VCI, which combines EPB and PCI, costs 378 379 \$490.93 (i.e., \$129.46 plus \$361.47) per 1,000 households. This is 4.5 times as much as lowest cost intervention (MDA). 380

381

382 <Insert Tables 2, 3, 4 and 5 about here>

383

384 **Proportions of inputs and activities**

Figure 2 presents the breakdown of costs by activity and intervention. Among the three interventions, PIC is the costliest. Among activities within each intervention, procurement of the materials and delivery of the service (termed procurement and delivery) was the costliest category. The non-personnel costs of VC were much higher

It is made available under a CC-BY 4.0 International license .

than those of the MDA program. As EPB and PIC are supplements to MDA, the arms

391

390

392 <Insert Figure 2 about here >

393

394 **Progress towards LF elimination in the study area**

with these interventions cost more than MDA alone.

Descriptive analyses showed a decline in microfilaria prevalence rates (MfP) for 395 village groups within each of the treatment conditions from 2010 through the end of 396 CRME's collection of entomological data in February 2013. Under MDA-alone, MfP fell 397 from its baseline levels (± standard error of the mean, using the approximation of a 398 399 normally distributed variable) by 84 (±25) percentage points. Where MDA was augmented by VC, villages with VCS reduced MfP by 75 (±20) and villages with VCI 400 reduced MfP by 90 (±22) percentage points, respectively. All reductions compared to 401 402 baseline levels were statistically significant [27]. Similarly, the "disease-free" share of population (i.e., living in villages with MfP below 1%) increased from 17% to 83% (66 403 404 percentage point improvement) in villages with MDA alone, from 8% to 67% (59 405 percentage point improvement) in VCS villages, and from 17% to 92% in VCI villages (75 percentage point improvement). 406

The percentages of villages with elimination are shown in Figure 3 for MfP and Figure 4 for AgP. Figure 5 shows the average AgP by study area and year. Similar to the results for average prevalence, all arms showed substantial improvement over time.

It is made available under a CC-BY 4.0 International license .

- However, the ranking of arms varied by year and by indicator, suggesting that no single
- 411 arm had dramatically superior results.
- 412
- 413 <Insert Figure 3 about here >
- 414 <Insert Figure 4 about here >
- 415 <Insert Figure 5 about here >
- Using the AgP measure for each intervention, the relative reductions from 2010
- to 2013 were similar to those for MfP: 70 percentage points for MDA-alone, 89
- 418 percentage points for VCS, and 79 percentage points for VCI.

419 Elimination results and context

Table 6 summarizes the results of the logistic regressions on the effectiveness of 420 the two LF measures. The variable Year2013 is highly significant, indicating marked 421 progress towards elimination in all arms. However, none of the coefficients for 422 423 interactions between Year2013 and intervention were statistically significant. Furthermore, for each VC arm (VCS and VCI), the coefficients for MfP and AgP were of 424 opposite sign. This lack of consistency and absence of statistical significance indicates 425 426 that the differences between MDA alone and MDA supplemented by VC initiatives were consistent with chance. That is, at the time and place of the randomized trial, neither 427 VCS nor VCI offered any statistically significant incremental benefit. 428

429

430 <Insert Table 6 about here>

It is made available under a CC-BY 4.0 International license .

431

432	As context, Figure 6 presents both the global and India national prevalence of LF					
433	from 1990 through 2019 based on the GBD study [52]. Over this period of almost three					
434	decades, the prevalence of LF declined by three quarters both globally and in India. Yet					
435	the prevalence rate in India remained about triple the global average. The latest (2019)					
436	prevalence rates of 2.7% in India and 0.9% globally translate to 37.2 and 71.9 million					
437	people affected in India and globally respectively. Of all people affected globally, 52%					
438	are in India, indicating that LF remained a serious public health problem in India. By					
439	dividing the DALY burden by the prevalence of LF in the GBD study, we found that each					
440	person-year of LF carried a 0.022 DALY burden. In other words, every 45 persons with					
441	LF constitute the loss in value equivalent to one year of good health (i.e., 1/0.022 = 45).					
442						
443	<insert 6="" about="" figure="" here="">.</insert>					
444						
445	Incremental cost-effectiveness ratio and summary results					
446	Table 7 derives the ICER of MDA, the one intervention that was significantly					
447	effective. MDA significantly improved (lowered) both MfP and AfP compared to initial					
448	values 3 years earlier. The ICER for MDA is \$112 per DALY. This ICER is substantially					
449	lower than India's 2010 threshold of \$1,350.6 per capita GDP in 2010 US dollars from					

the World Bank [53].

It is made available under a CC-BY 4.0 International license .

452	<insert 7="" about="" here="" table=""></insert>
453	
454	Discussion
455	This study documents substantial progress in controlling LF in the study area
456	from 2010 through 2013, as well as over a period of almost 3 decades across all of
457	India and globally. This progress was achieved largely through MDA. Yet, despite
458	MDA, an estimated 37.2 million people in India remained affected by LF in the latest
459	data (2019) [52]. A key policy question is whether existing control strategies are
460	sufficient, or whether VC must be added as well.
461	This study was planned when the impact of MDA on LF had slowed, and MDA
462	appeared insufficient to be able to eliminate LF as a public health problem in India.
463	Supplementing MDA by one or both VC strategies was hypothesized to make a
464	potentially crucial difference. The goals of this study were to assess the cost,
465	effectiveness, and cost-effectiveness of MDA and the VC strategies as complements to
466	MDA.
467	Prior to the study period, the impact of MDA was mixed. Tamil Nadu began
468	single dose DEC mass drug administration (MDA) from 1997-98 in all endemic districts
469	and switched to a two-drug regimen of DEC and albendazole in 2001 [54]. However,
470	gaps in annual rounds occurred 1997, 2005 and 2006 in Tamil Nadu. Over the study
471	period, however, MDA proved substantially more efficacious than it had previously. We
472	counted 11 completed MDA rounds for our study villages in Villupuram District during
473	the 15-year period ending in 2012. According to WHO's protocols for LF chemotherapy
474	[55], after five rounds of MDA the implementation units could stop the interventions if
	22

It is made available under a CC-BY 4.0 International license .

475they had achieved \geq 65% program coverage during each of the five rounds and had476reached the target levels of MfP<1% or AgP<2%. A period of post-treatment</td>477surveillance would follow to be sure that LF transmission had been interrupted. In 2012,478the district ended its MDA program [56].

The study data found that MDA was effective and highly cost-effective in 479 controlling LF and progressing towards elimination. Improvements in adherence may 480 481 explain the success of MDA in the study site compared to earlier expectations. An evaluation of Tamil Nadu's MDA program in 2000 found mediocre adherence, with 30% 482 households being missed and 46% of those covered not swallowing the recommended 483 484 MDA tablets [50]. Our interviewees reported, however, that MDA delivery rates and compliance have progressively improved over the subsequent years, consistent with the 485 steady declines in MfP and AgP under MDA alone. As MDA is delivered by community-486 level workers with support from higher levels in the health system, its efficacy 487 demonstrates success of Tamil Nadu's system of social mobilization and human 488 development. The finding is consistent with the State's ranking as one of India's best 489 on this dimension [57]. 490

As far as we know, this study is the only comparative cost-effectiveness study of alternative LF control strategies. This study did not find a statistically significant incremental progress towards LF elimination as a public health problem from either VC intervention. We concluded that VCS and VCI were not significantly effective nor costeffective additions to MDA during the study period in this setting. Thus, this study did not find quantitative evidence within the 3-year study period to support the addition of

It is made available under a CC-BY 4.0 International license .

497 VC. Continuing with high coverage and full compliance with the regimen of medicines 498 (MDA), rather than adding VC, proved to be the most effective use of limited resources. 499 The reason why VC failed to demonstrate incremental impact might be attributable to the presence of numerous untreated breeding sites for *Culex* 500 501 quinquefasciatus, such as blocked drains, buckets, discarded containers and obscure disused cesspits, which yielded sufficient mosquitoes for continuing LF transmission. To 502 address this challenge the NVBDCP has relied on more integrated VC strategies similar 503 to VCI [58] but we are not aware of any cost-effectiveness evaluation. 504 After 2015, the Transmission Assessment Survey found that 222 of the 256 505 districts previously classified as endemic for LF had MfP adequately controlled [59]. 506 Most of these districts have stopped their MDA programs as they were no longer 507 needed. However, 12 such villages in non-endemic areas had MfP between 3.2% and 508 11.2% [60]. 509 Qualitative observations and entomological data identified some potential 510 benefits of VCI. Mosquito nuisance was reduced. Also, curtains can protect 511 households from other insects in addition to mosquitoes, thereby reducing transmission 512 513 risks for malaria, arboviruses, leishmaniasis and other infections. As VC is less dependent on individual behavior than MDA, it could potentially achieve higher 514 coverage and compliance. Both VC interventions were reported to heighten the public's 515 awareness of LF and capacity to control it, and perhaps improved compliance with MDA 516 [27]. However, unless these added benefits were quantified and proved to be 517 substantial, they cannot justify the incremental expense of VC. 518

It is made available under a CC-BY 4.0 International license .

519	Two opposing study limitations must be acknowledged. On the one hand, our
520	collection of data for costs of MDA was retrospective and may have missed hidden
521	costs of some extended activities, such as more days for MDA distribution, and
522	contributed time from other government departments. On the other hand, costs in this
523	trial may have been higher than those that would have been routinely found. Donor
524	funding allowed engaging more and higher skilled staff. As a first-time effort, some
525	experimentation required additional time. If VC had been funded entirely from Indian
526	sources, procurement procedures might have been faster and less expensive.
527	
528	Conclusion
529	Before-and-after data in this trial indicate that MDA was highly effective in
530	controlling LF as measured by both MfP and AgP. This success left little scope for
531	further improvement. With substantially reduced levels of LF, the study did not find any
532	significant additional benefits that VC added to MDA over the 3-year study period. This
533	study did not assess whether VC could have replaced MDA or proven more impactful
534	over a longer timeframe. However, our cost data show that VC would probably remain
535	more expensive than MDA. As India's 2.7% LF prevalence persists at three times the
536	global average [52], the goal of elimination justifies continuing MDA, possibly using
537	triple-drug therapy [61], in communities where LF rates remain above 2% AgP or 1%
538	MfP thresholds.
539	
540	Acknowledgments

It is made available under a CC-BY 4.0 International license .

We thank: Eric Ottesen, PJ Hooper, the late Dominique Kyelem and other 542 543 personnel of the Task Force for Global Health for thoughtful ideas and logistical and 544 financial support; the late S. Elango, S. Sreedharan, and M. Alamelu of the State Public Health Department of Tamil Nadu; M. Geetha, C. Palanichamy, and other health staff of 545 546 the health unit district of Kallakurichi; Muthu Kumar, T. Sekar, T.A. Srinivasan, and other staff of the Ariyur Block PHC for providing key program and financial information; health 547 inspectors, village health nurses, other medical officers, and village presidents, the late 548 R. Rajendran, A. Munirathinam, S. Ravi, and V. Ashok Kumar of CRME for providing 549 550 essential program data during our field visits; the volunteer program workers for their critical contributions to the MDA and VC services underlying this study; and Clare L. 551 552 Hurley of Brandeis University for editorial support.

553

554 Emails

- 555 Donald S Shepard, Ph.D. shepard@brandeis.edu
- 556 Aung K Lwin M.D., M.S, aklwin@brandeis.edu
- 557 Sunish I. Pulikkottil, Ph.D., sunish67@yahoo.com
- 558 Mariapillai Kalimuthu, MS, smilekali@gmail.com
- 559 Natarajan Arunachalam, Ph.D., arunachalam10@yahoo.com
- 560 Brij K. Tyagi Ph.D., abktyagi@gmail.com
- 561 Graham B. White Ph.D., gbwhite@ufl.edu

It is made available under a CC-BY 4.0 International license .

563 **References**

World Health Organization (WHO). Integrating neglected tropical diseases into 564 1. 565 global health and development: Fourth WHO report on neglected tropical diseases. Geneva: WHO; 2017. Available from: WHO/HTM/NTD/2017.01, 278pp. 566 2. Dhariwal AC, Srivastava PK, Bhattacharjee J. Elimination of lymphatic filariasis in 567 India: An update. J Ind Med Assoc. 2015;113(12):189-90 PubMed Central 568 PMCID: 19552103. 569 3. Lobo DA, Velayudhan R, Chatterjee P, Kohli H, Hotez PJ. The neglected tropical 570 diseases of India and South Asia: Review of their prevalence, distribution, and 571 control or elimination. PLoS Negl Trop Dis. 2011;5(10): e1222. 572 doi:10.1371/journal.pntd.0001222. 573 4. Ramaiah KD, Das PK. Mass drug administration to eliminate lymphatic filariasis 574 in India. Trends Parasitol. 2004;20(11):499-502. doi: 10.1016/j.pt.2004.08.010. 575 5. Tyagi BK (Ed.). Lymphatic Filariasis Epidemiology, Treatment and Prevention -576 The Indian Perspective. Singapore: Springer Nature; 2018. xix+333pp. 577 https://link.springer.com/book/10.1007/978-981-13-391-2 p. 578 579 6. Kumar P, Ahmad S, Bhar D, Roy R, Singh B. Whenever I tell her to wear slippers, she turns a deaf ear. She never listens': A qualitative descriptive 580 research on the barriers to basic lymphedema management and guality of life in 581 lymphatic filariasis patients in a rural block of eastern India Parasit Vectors. 582 2023;16(1):429. doi: 10.1186/s13071-023-06036-0. 583 7. World Health Organization. Global programme to eliminate lymphatic filariasis: 584 progress report, 2021. Wkly Epidemiol Rec, 97, 513–524. 2022. Available from: 585

It is made available under a CC-BY 4.0 International license .

586		https://iris.who.int/bitstream/handle/10665/363513/WER9741-eng-
587		fre.pdf?sequence=.
588	8.	World Health Organization (WHO). Lymphatic filariasis: Key facts. 2023.
589		Available from: https://www.who.int/news-room/fact-sheets/detail/lymphatic-
590		filariasis.
591	9.	Agrawal VK, Sashindran VK. Lymphatic filariasis in India: problems, challenges
592		and new initiatives. Med J Armed Forces India. 2006;62(4):359-62. doi:
593		10.1016/S0377-1237(06)80109-7.
594	10.	Global Alliance to Eliminate Lymphatic Filariasis (GAELF). Global Alliance to
595		Eliminate Lymphatic Filariasis, Report of the Second Meeting. New Delhi, India:
596		2-3 May 2002.
597	11.	World Health Organization (WHO). Annual Report on Lymphatic Filariasis 2001.
598		Global Programme to Eliminate Lymphatic Filariasis. 2002. Available from:
599		WHO/CDS/CPE/CEE/2002.28, 81.
600	12.	Kalimuthu M, Sunish IP, Nagaraj J, Munirathinam A, Ashok Kumar V,
601		Arunachalam N, et al. Residual microfilaraemia in rural pockets of south India
602		after five rounds of DEC plus albendazole administration as part of the LF
603		elimination campaign. J Vector Borne Dis. 2015;52(6):182-4. PMID: 26119554.
604	13.	Babu BV, Babu GR. Coverage of, and compliance with, mass drug administration
605		under the programme to eliminate lymphatic filariasis in India: A systematic
606		review. Trans R Soc Trop Med Hyg. 2014;108(9):538–49. doi:
607		10.1093/trstmh/tru057.

It is made available under a CC-BY 4.0 International license .

- 14. Jambulingam P, Subramanian S, de Vlas SJ, Vinubala C, Stolk WA.
- 609 Mathematical modelling of lymphatic filariasis elimination programmes in India:
- 610 required duration of mass drug administration and post-treatment level of
- 611 infection indicators. Parasit Vectors 2016;9:501. doi 10.1186/s13071-016-1768-
- 612
- 15. Ramaiah KD, Das PK, Michael E, Guyatt H. The economic burden of lymphatic
- filariasis in India. Parasitol Today. 2000;16(6):251-3. doi: 10.1016/s0169-
- 615 **4758(00)01643-4**.

у.

- 16. Zagaria N, Savioli L. Elimination of lymphatic filariasis: A public-health challenge.
- Ann Trop Med Parasitol. 2002;96(Suppl 2):S3-13. doi:
- 618 10.1179/00034980215002347.
- 17. Raju K, Jambulingam P, Sabesan S, Vanamail P. Lymphatic filariasis in India:
- Epidemiology and control measures. J Postgrad Med. 2010;56(3):232-8. doi:
- 621 **10.4103/0022-3859.68650**.
- 18. World Health Organization (WHO). Integrated vector management to control
- 623 malaria and lymphatic filariasis: WHO position statement. 2011. Available from:
- https://apps.who.int/iris/handle/10665/70817.
- 19. World Health Organization (WHO). Lymphatic filariasis: A handbook of practical
- entomology for national lymphatic filariasis elimination programmes. 2013.
- 627 Available from: WHO/HTM/NTD/PCT/2013.10.
- 20. Bockarie MJ, Pedersen EM, White GB, Michael E. Role of vector control in the
- 629 Global Program to Eliminate Lymphatic Filariasis. Annu Rev Entomol.
- 630 2009;54:469–87. doi: 10.1146/annurev.ento.54.110807.090626.

It is made available under a CC-BY 4.0 International license .

- 631 21. Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the
- control/elimination of lymphatic filariasis. Bull World Health Organ.
- 633 1997;75(6):491-503, PMID: 9509621.
- 634 22. Reuben R, Rajendran R, Sunish IP, Mani TR, Tewari SC, Hiriyan J, et al. Annual
- single dose diethylcarbamazine plus ivermectin for control of bancroftian
- 636 filariasis: Comparative efficacy with and without vector control. Ann Trop Med
- 637 Parasitol. 2007;95(4):361-78. doi: 10.1080/00034980120065796.
- 638 23. Sunish IP, Rajendran R, Mani TR, Munirathinam A, Tewari SC, Hiriyan J, et al.
- 639 Resurgence in filarial transmission after withdrawal of mass drug administration
- and the relationship between antigenaemia and microfilaraemia A longitudinal
- study. Trop Med Int Health. 2002;7(1): 59-69. doi: 10.1046/j.1365-
- 642 3156.2002.00828.x.
- 643 24. Sunish IP, Rajendran R, Mani TR, Munirathinam A, Tewari SC, Hiriyan J, et al.
- 644 Transmission intensity index to monitor filariasis infection pressure in vectors for
- the evaluation of filariasis elimination programmes. Trop Med Int Health.

646 2003;8(9):812–9. doi: 10.1046/j.1365-3156.2003.01109.x.

- 647 25. Krishnamoorthy K, Rajendran R, Sunish I, Reuben R. Cost-effectiveness of the
- use of vector control and mass drug administration, separately or in combination,
- against lymphatic filariasis. Ann Trop Med Parasitol. 2002;96(Supplement
- 650 2):S77-90. doi: 10.1179/000349802125002428.
- 26. Sunish IP, Rajendran R, Arunachalam N, Munirathinan A, Tyagi BK, Elango S, et
- al. Assessment of the Added Impact of Vector Control for Augmentation of MDA
- to Eliminate Lymphatic Filariasis in South India. Final Report, August 2008 to

It is made available under a CC-BY 4.0 International license .

- July 2013. BMGF Funded project through RCC-ELF Grant 43922. Centre for
- 655 Research in Medical Entomology (Indian Council for Medical Research),
- 656 Madurai, Tamil Nadu. 2014.
- 657 27. Sunish I, Kalimuthu M, Ashok Kumar V, Munirathinam A, Nagaraj J, Tyagi BK, et
- al. Can community-based integrated vector control hasten the process of LF
- elimination? Parasitol Res. 2016;115:2353–62. doi: 10.1007/s00436-016-4985-6.
- 660 28. Sunish IP, Rajendran R, Mani TR, Munirathinam A, Dash AP, Tyagi BK. Vector
- 661 control complements mass drug administration against Bancroftian filariasis in
- Tirukoilur, India. Bull World Health Organ. 2007;85:138-45. doi:
- 663 10.2471/blt.06.029389.
- 664 29. CCI. Census of India 2011, Provisional Population Total. Census Commissioner
- India, Office of the Registrar General, Ministry of Home Affairs, Government of
- India, New Delhi. 2011.
- 667 30. Sabesan S, Raju KH, Subramanian S, Srivastava PK, Jambulingam P.
- 668 Lymphatic filariasis transmission risk map of India, based on a geo-
- 669 environmental risk model. Vector Borne Zoonotic Dis. 2013;13(9):657-65. doi:
- 670 10.1089/vbz.2012.1238.
- 31. Subramanian NT. Annual Public Health Administration Report 2008-09.
- 672 Chennai: Government of Tamil Nadu, 2009.
- 673 32. National Health Mission Tamil Nadu. Department of Health and Family Welfare,
- 674 State Health Society, Chennai. Available from:
- 675 http://www.nrhmtn.gov.in/hud.html.

It is made available under a CC-BY 4.0 International license .

- 33. World Health Organization (WHO). Monitoring and Epidemiological Assessment
- of Mass Drug Administration in the Global Programme to Eliminate Lymphatic
- 678 Filariasis: A Manual for National Elimination Programmes. 2011. Available from:
- 679 WHO/HTM/NTD/PCT/2011.4.
- 680 34. Rebollo M, Bockarie M. Toward the elimination of lymphatic filariasis by 2020:
- treatment update and impact assessment for the endgame. Expert Rev Anti

682 Infect Ther. 2013;11(7):723-31. doi: 10.1586/14787210.2013.811841.

- 683 35. Rajendran R, Sunish IP, Munirathinam A, Kumar VA, Tyagi BK. Role of
- community empowerment in the elimination of lymphatic filariasis in south India.
- 685 Trop Biomed. 2010;27(1):68-78. PMID: 20562816.
- 686 36. Bajpai N, Dholakia RH, Sachs JD. Scaling Up Primary Health Services in Rural
- Tamil Nadu: Public Investment Requirements and Health Sector Reform. New
- 688 York: The Earth Institute at Columbia University, Center on Globalization and
- 689 Sustainable Development Working Paper No.36, 65p. Academic Commons,
- 690 https://doi.org/10.7916/D8R49XMW. 2008.
- 691 37. GlaxoSmithKline. Albendazole donation programme. Available from:
- 692 https://www.gsk.com/media/3350/albendazole-donation-programme-

693 infographic.pdf.

- 694 38. World Health Organizaiton (WHO). Control of Neglected Tropical Diseases.
- Global Programme to Eliminate Lymphatic Filariasis. 2023. Available from:
- 696 https://www.who.int/teams/control-of-neglected-tropical-diseases/lymphatic-
- 697 filariasis/global-programme-to-eliminate-lymphatic-filariasis.

- 698 39. Maxwell CA, Curtis CF, Haji H, Kisumku S, Thalib AI, Yahya SA. Control of
- 699 Bancroftian filariasis by integrating therapy with vector control using polystyrene
- beads in wet pit latrines. Trans R Soc Trop Med Hyg. 1990;84(5):709-14. doi:
- 701 10.1016/0035-9203(90)90158-b.
- 40. Curtis C, Lines J, Carnevale P, Robert V, Boudin C, Halna J, et al. Impregnated
- bed nets and curtains against malaria mosquitoes. In: Curtis C, editor.
- Appropriate Technology in Vector Control. Boca Raton FL: CRC Press; 1990. pp.5-46.
- 41. Curtis CF, Malecela-Lazaro M, Reuben R, Maxwell CA. Use of floating layers of
- polystyrene beads to control populations of the filaria vector Culex
- 708 quinquefasciatus. Ann Trop Med Parasitol. 2002;96(Suppl 2):S97-S104. doi:
- 709 10.1179/000349802125002446.
- 42. Government of India. National Conter for Vector Borne Disease Control. 2023.
- 711 Available from: https://ncvbdc.mohfw.gov.in/.
- Frye JE. International Drug Price Indicator Guide, 2009 edition. Cambridge, MA:
 Management Sciences for Health, 2010.
- 44. Linehan M, Hanson C, Weaver A, Baker M, Kabore A, Zoerhoff KL, et al.
- 715 Integrated implementation of programs targeting neglected tropical diseases
- through preventive chemotherapy: Proving the feasibility at national scale. Am J
- Trop Med Hyg. 2011;84(1):5-14. doi: https://doi.org/10.4269/ajtmh.2011.10-0411.
- 45. World Health Organizaiton (WHO). Neglected Tropical Diseases. 2017. Available
- from: http://www.who.int/neglected_diseases/diseases/en/.

It is made available under a CC-BY 4.0 International license .

		It is made available under a CC-BY 4.0 International license .
720	46.	XE. Current and Historical Rate Tables - 17 Jan 2010 - Indian Rupee. Available
721		from: http://www.xe.com/currencytables/?from=INR&date=2010-01-17.
722	47.	Mladonicky JM, King JD, Liang JL, Chambers E, Pa'au M, Schmaedick MA, et al.
723		Assessing transmission of lymphatic filariasis using parasitologic, serologic, and
724		entomologic tools after mass drug administration in American Samoa. Am J Trop
725		Med Hyg. 2009;80(5):769-73. PMID: 19407122.
726	48.	Pani SP, Hoti SL, Vanamail P, Das LK. Comparison of an
727		immunochromatographic card test with night blood smear examination for
728		detection of Wuchereria bancrofti microfilaria carriers. Natl Med J India.
729		2004;17(6):304-6. PMID: 15736550.
730	49.	Schuetz A, Addiss DG, Eberhard ML, Lammie PJ. Evaluation of the whole blood
731		filariasis ICT test for short-term monitoring after antifilarial treatment. Am J Trop
732		Med Hyg. 2000;62(4):502-3. doi: 10.4269/ajtmh.2000.62.502.
733	50.	Ramaiah KD, Das PK, Appavoo NC, Ramu K, Augustin DJ, Kumar KN, et al. A
734		programme to eliminate lymphatic filariasis in Tamil Nadu state, India:
735		compliance with annual single-dose DEC mass treatment and some related
736		operational aspects. Trop Med Int Health. 2000;5(12):842-7. doi: 10.1046/j.1365-
737		3156.2000.00659.x.
738	51.	Turner HC, Bettis AA, Chu BK, McFarland DA, Hooper PJ, Ottesen EA, et al. The
739		health and economic benefits of the global programme to eliminate lymphatic
740		filariasis (2000–2014). Infect Dis Poverty 2016;5:54. doi: 10.1186/s40249-016-
741		0147-4.

It is made available under a CC-BY 4.0 International license .

- 52. Institute of Health Metrics and Evaluation. Global Health Data Exchange.
- Lymphatic filariasis. 2023. Available from: https://vizhub.healthdata.org/gbd-results/.
- 53. The World Bank. GDP per capita (current US \$) India. 2023. Available from:
- 746 https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=IN
- 54. Nandha B, Krishnamoorthy K, Jambulingam P. Towards elimination of lymphatic
- filariasis: Social mobilization issues and challenges in mass drug administration
- with anti-filarial drugs in Tamil Nadu, South India. Health Educ Res.
- 750 2013;28(4):591-8. doi: 10.1093/her/cyt042.
- 751 55. Chu BK, Deming M, Biritwum N-K, Bougma WR, Dorkenoo AM, El-Setouhy M, et
- al. Transmission assessment surveys (TAS) to define endpoints for lymphatic
- filariasis mass drug administration: A multicenter evaluation. PLoS Negl Trop Dis.
- 754 2013;203:e2584. doi:10.1371/journal.pntd.0002584.
- 755 56. National Health Mission Tamil Nadu, Department of Health and Family Welfare.
- 756 Vector Borne Disease Control Programme, State Health Society, Chennai.
- 757 Available from: http://www.nrhmtn.gov.in/vbdc.html.
- 57. Drèze J, Sen A. An Uncertain Glory: India and its Contradiction. Princeton
- 759 University Press, NJ: Princeton University Press, NJ; 2013.
- 58. Srivastava PK, Sonal GS, Sharma SN, Singh S, Baruah K. Integrated Vector
- 761 Management: Scenario Under National Vector Borne Disease Control Program,
- 762 India. J Ind Med Assoc. 2015;113(12):179-82.

It is made available under a CC-BY 4.0 International license .

763	59.	Srivastava PK, Dhariwal AC. Lymphatic Filariasis Elimination: Update for Mission
764		Possible. 2018. Available from: https://link.springer.com/chapter/10.1007/978-
765		981-13-1391-2_2.
766	60.	Srividya A, Subramanian S, Jambulingam P, Vijayakumar B, Raja JD. Mapping
767		and monitoring for a lymphatic filariasis elimination program: A systematic
768		review. Res Rep Trop Med. 2019;10:43-90. doi: 10.2147/RRTM.S134186.
769	61.	Tripathi B, Roy N, Dhingra N. Introduction of triple-drug therapy for accelerating
770		lymphatic filariasis elimination in India: lessons learned. Am J Trop Med Hyg,
771		2022;106(Suppl 5): 29–38.

It is made available under a CC-BY 4.0 International license .

773 Tables

Table 1: Management levels supporting the LF mass drug administration (MDA) program in the study area and corresponding populations covered

776

Management level	Staff	Population covered
1. State Health Department (SHD) of Tamil Nadu	Members of Task Force and Advisory Committees; Supervisory Team	31,250,000
2. Health Unit District (HUD) of Kallakurichi	HUD supervisory team: Deputy Director of Health Services, District Staff Assistant, District Malaria Officer, District Health Inspectors*, Medical College Entomologists*, HUD Rapid Response Team;	1,589,500
3. Block Primary Health Center (PHC) of Ariyur	Block PHC supervisory team: Block Medical Officer*, Assistant Medical Officer at block, Assistant Medical Officer of additional PHC, Block Health Supervisor, Non-medical Supervisor, Block Extension Educator, Community Health Nurse at block PHC, Sector Health Nurse at block PHC, Health Inspector (MDA in-charge) at Block Health Supervisor*, Non-medical Supervisor , Block Extension Educator*, Community Health Nurse, Sector Health Nurse, Pharmacist*,Sanitary Worker, Driver; Block PHC Rapid Response Team	116,822
4. Subcenter	Village Health Nurse *	5,000
5. Village	Involved villagers	1,639
6. 50 households	Village volunteers *	250

* Indicates survey respondents. Note: mlowest. LF denotes lymphatic filariaisis.

It is made available under a CC-BY 4.0 International license .

780 Table 2: Useful life spans and targets of MDA and VC inputs

	Useful life	
Inputs	(years)	Intervention targets
Mass drug administration (MDA)		
Sensitization by government.	1	All residents
Drugs	1	All residents
<u>Vector control (VC)</u> <i>Both interventions</i> Peer sensitization of villagers	5	All residents
Expanded polystryene beads (EPB)		
Cesspit modification	3	Cesspits (1 pit per 27 households)
Application of beads	1	Wells (1 well per 55 households)
Pyrethroid impregnated curtains (PIC)		
Curtain material	3	All houses (1 house per 5 persons)
Spray	0.5	All houses (1 house per 5 persons)

It is made available under a CC-BY 4.0 International license .

782 Table 3: Annualized costs per 1,000 population at the village level (US\$)

	Unit		<u>mber of ι</u>			<u> costs (L</u>	
Input	cost (US\$)	MDA	EPB	PIC	MDA	EPB	PIC
	· · ·	nto offer		(bouro)			
Village president	<u>ige reside</u> 0.56	<u>9.76</u>		(nours)	5.46		
Village vice-president	0.45	9.76			4.37		
Village ward member	0.45	29.29			13.10		
Others (e.g., previous	2.24	19.52			43.66		
presidents)	2.27	10.02			40.00		
, ,	residents	offered	EPB & P	IC (hours)			
Personnel				- \			
Village president	0.52		1.17	1.58		0.61	0.8
Village vice-president	0.42		0.26	0.47		0.11	0.2
Village ward member	0.45		4.08	2.58		1.82	1.1
Village president's ass't	0.22		4.18	8.00		0.91	1.7
Village ward member's ass't	0.22		11.90	16.05		2.60	3.5
Household head (procuring	0.22		0.82	276.58		0.18	60.3
products)							
Village laborer	0.05		2.38			0.13	
Village meeting participant	0.14		13.34			1.87	
Secondary school student	0.04			174.68			7.7
Mason	0.61		1.77			1.09	
Mason's helper	0.31		1.71			0.52	
Well cleaner	0.61		3.51			2.16	
Well cleaner's helper	0.12		2.11			0.26	
Village volunteer	0.22		22.84	64.41		4.99	14.0
Demonstration participant	0.22			13.97			3.0
PIC impregnator	0.22			69.87			15.2
Neighborhood helper	0.22			174.68			38.1
Other village residents	0.14			27.29			3.8
attending demonstration	0.00			0.40			~ ~
Tailor Tailaría halaan	0.68			3.49			2.3
Tailor's helper	0.23			3.49			0.7
Sprayer	1.53			9.36			14.3
Subtotal personnel					66.6	17.2	167.
Non-personnel							
Expanded beads (kg)	3.8		28.2			107.8	
Curtain fabric (m²)	0.49			351.6			173.
Other for EPB treatment	0.004		1100			4.4	
Other for PIC treatment	0.020			1025	_		20.
Subtotal non-personnel					0.00	112.2	194
Total (all resources)					66.6	129.5	361

- Notation: MDA denotes mass drug administration; EPB denotes expanded polystyrene
- beads; PIC denotes pyrethroid impregnated curtains; VC denotes vector control; hr
- denotes hour; kg denotes kilograms, m² denotes square meter.
- Note: Total costs equal unit cost times the quantity. Quantities shown in the table arerounded.

It is made available under a CC-BY 4.0 International license .

Table 4: Annualized costs (US\$) per 1,000 population at the block primary health 790 care level

791

Input	Unit	<u>Number of units</u>			<u>Total cost (US\$)</u>			
Input	cost	MDA	EPB	PIC	MDA	EPB	PIC	
Block primary health								
<u>center staff (hours)</u>								
Medical officers	\$4.8	2.3	0.4	0.4	11.3	2.1	2.1	
Public health	\$4.5	3.2	0.7	0.7	14.4	3.0	3.0	
supervisors	·		0.1	0.1		0.0	0.0	
Nurses	\$4.0	2.6			10.2			
Health inspectors	\$3.5	4.7	3.0	3.0	16.5	10.7	10.7	
Assistant field workers	\$2.5	1.7			4.1			
Administration workers	\$2.5	1.2			2.9			
Press people	\$2.2	0.5			1.1			
Personnel others	\$5.3	7.7			41.2			
<u>VC project staff (hours)</u>								
Lead persons	\$5.5		5.8	5.8		31.9	31.9	
Project officers	\$1.6		11.4	11.4		17.6	17.6	
Technicians	\$0.6		15.0	15.0		9.6	9.6	
Project assistants	\$0.4		90.9	90.9		31.8	31.8	
Project administrators	\$1.1		3.8	3.8		4.3	4.3	
Volunteers	\$0.01		930.0	930.0		9.3	9.3	
Subtotal Personnel					101.7	120.2	120.2	
Non-personnel								
Expanded beads (kg)	\$0.1		1010.0			111.1		
Curtain fabric (square meter)	\$0.2			998.9			189.8	
Non-personnel, other	\$1.0		108.6	110.1		108.6	110.1	
Subtotal Non personnel					0.0	219.6	299.8	
Total (all resources)					101.7	339.8	420.0	

Notation: MDA denotes mass drug administration; EPB denotes expanded polystyrene 792 beads; PIC denotes pyrethroid impregnated curtains; VC denotes vector control; hr 793 denotes hour; kg denotes kilograms, n.a. denotes not applicable (various inputs). 794 Notes: Total costs equals unit cost times quantity. Volunteers were not paid for vector 795 control activities, but occasionally received refreshments. Unit costs for personnel are 796 hourly payments for paid staff, and average hourly refreshment costs for volunteers. 797 Non-personnel other is a composite of all other inputs, including transportation. The 798 quantities shown are rounded. 799 800

Table 5: Economic cost of interventions (US\$) by funder and management level (1,000 population)

MDA		EF	ЪВ	PIC		
Gov't	Comm.	Gov't	Comm.	Gov't	Comm.	
208.66	0.00	0.02	0.00	0.02	0.00	
3.58	0.00	1.29	0.00	1.67	0.00	
101.69	0.00	339.82	0.00	420.01	0.00	
99.24	0.00	20.34	0.00	20.34	0.00	
0.14	66.58	0.00	129.46	0.00	361.47	
<u>9.30</u>	<u>44.36</u>	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	
422.61	110.94	361.46	129.46	442.04	361.47	
	533.55		490.92		803.51	
	Gov't 208.66 3.58 101.69 99.24 0.14 <u>9.30</u>	Gov'tComm.208.660.003.580.00101.690.0099.240.000.1466.589.3044.36422.61110.94	Gov'tComm.Gov't208.660.000.023.580.001.29101.690.00339.8299.240.0020.340.1466.580.009.3044.360.00422.61110.94361.46	Gov'tComm.Gov'tComm.208.660.000.020.003.580.001.290.00101.690.00339.820.0099.240.0020.340.000.1466.580.00129.469.3044.360.000.00422.61110.94361.46129.46	Gov'tComm.Gov'tComm.Gov't208.660.000.020.000.023.580.001.290.001.67101.690.00339.820.00420.0199.240.0020.340.0020.340.1466.580.00129.460.009.3044.360.000.000.00422.61110.94361.46129.46442.04	

Notation: MDA denotes mass drug administration; EPB denotes expanded polystyrene

804 beads; PIC denotes pyrethroid impregnated curtains; Gov't denotes government;

805 Comm. denotes community; HUD denotes health unit district. Combined total sums

so6 costs funded by government and communities.

It is made available under a CC-BY 4.0 International license .

Independent	Coef-	Standard		Stat.	<u>95%</u>	CI			
variable	ficient	error	. Z	sig.	(lower,	upper)			
<u>A. Dependent variable: Microfilaria prevalence (MfP)</u>									
Year2013	-3.1333	0.7020	-4.46	0.00	-4.5219	-1.7446			
VCS	-0.1223	0.7020	-0.17	0.86	-1.5109	1.2664			
Year2013 x VCS	0.3679	0.9928	0.37	0.71	-1.5960	2.3317			
VCI	-1.1430	0.7020	-1.63	0.11	-2.5317	0.2456			
Year2013 x VCI	0.6418	0.9928	0.65	0.52	-1.3220	2.6057			
Constant	3.8502	0.4964	7.76	0.00	2.8682	4.8321			
<u>B.</u>	B. Dependent variable: Antigen prevalence (AgP)								
Year2013	-5.6983	2.3784	-2.40	0.02	-10.4041	-0.9925			
VCS	4.1813	2.2678	1.84	0.07	-0.30556	8.668			
Year2013 x VCS	-4.8591	3.3216	-1.46	0.15	-11.4312	1.7128			
VCI	2.8138	2.2678	1.24	0.22	-1.6731	7.3006			
Year2013 x VCI	-2.9325	3.2863	-0.89	0.37	-9.4345	3.5694			
Constant	8.0779	1.6035	5.04	0.00	4.9053	11.2506			

Table 6: Linear regression results of incremental impact of vector control

808

Notes: Each panel is based as cross-section time series data with 144 observations 809 (36 villages times 4 years). Mass drug administration (MDA) serves as the reference; 810 VCS denotes vector control singular, using only expanded polystyrene beads; VCI 811 combines VCS with pyrethroid impregnated curtains; CI denotes confidence interval; 812 Comparator for MDA is no intervention; comparator for VCI and VCS is MDA; 813 Independent variables year 2013 shows the impact of MDA in 2013 relative to the 814 reference year (2010). VCS and VCI show the difference in average prevalence levels 815 of villages in these arms compared to those in the MDA arm. The interaction terms 816 show the impacts of vector control compared to MDA alone in 2013. Negative coefficients 817 indicate favorable progress towrard eliminiation of LF. Stat. sig. denotes statistical 818 signficance (two-sided) based on normal distribution for the coefficient. R-squared is 819 820 0.31 for regression A (MfP) and 0.28 for regression B (AgP).

It is made available under a CC-BY 4.0 International license .

Table 7. Derivation of the incremental cost-effectiveness ratio of MDA (2010 US dollars)

Row	Component	Source	Value
(1)	Baseline (2010) % of villages with MfP<1%	Figure 3	17%
(2)	Final (2013) % of villages with MfP<1%	Figure 3	83%
(3)	Cumulative change in % of villages with MfP<1%	(2) - (1)	66%
(4)	Average annual increase in % of villages with MfP<1%	(3) / 3	22.0%
(5)	Baseline (2010) % of villages with AgP<2%	Figure 4	8%
(6)	Final (2013) % of villages with AgP<2%	Figure 4	60%
(7)	Cumulative change in % of villages with AfP<2%	(6) - (5)	52%
(8)	Average annual increase in % of villages with AfP<2%	(7) / 3	17.3%
(9)	Pooled annual increase in % of villages with MfP<1% and AfP<2%	[(4) + (8)] / 2	19.7%
(10)	Implicit comparator to MDA	Text	No
()			prevention
(11)	Incremental % of villages with MfP<1% and AgP<2%	(9) - (10)	19.7%
(12)	DALYs per person with lymphatic filariasis (LF)	GBD Study	0.022
(13)	DALYs per 1,000 persons with LF	1,000 x (12)	22
(14)	DALYs averted per 1,000 persons in arm	(11) x (13)	4.33
(15)	Overall cost per 1,000 population	Table 5	\$533.35
(16)	Incremental cost per 1,000 population	(15) - (10)	\$533.35
(17)	Incremental cost-effectiveness ratio (ICER), \$/DALY	(16) / (14)	\$112
(18)	India's 2010 per capita Gross Domestic Product (GDP) in 2010 US\$	World Bank†	\$1,350.6
(19)	ICER as fraction of India's per capita GDP	(17) / (18)	8%

823


Notes: DALY denotes disability adjusted life years; MDA denotes mass drug

administration; MfP denotes microfilaria prevalence in vllage during the year; AgP

denotes antigen prevalence in the village during the year. † Source: The World


827 Bank[53].

Figure 1: Map of study villages by treatment arm in lymphatic filariasis vector control (LF-VC) project funded by the Bill & Melinda Gates Foundation (BMGF)



It is made available under a CC-BY 4.0 International license .

Figure 2: Cost per person per year by intervention and activity (US\$)



832

Notation: MDA denotes mass drug administration; EPB denotes expanded polystyrene

beads); PIC denotes pyrethroid impregnated curtains. The dollar amounts are costs per

person per year of the activities. Note that villages receiving EPB also received MDA.

836 Villages receiving PIC also received MDA and EPB





Figure 3: Share of villages achieving micro-filaria prevalence (MfP) target by intervention arm

Notes: MfP denotes microfilaria prevalence; MDA denotes mass drug administration; VCS denotes vector control single; VCI denotes vector control integrated; MfP<1% means the village has reached the lymphatic filariasis (LF) elimination threshold.




843 Figure 4: Share of villages achieving antigen prevalence (AgP) target by intervention arm

846 Notes: MDA denotes mass drug administration; VCS denotes vector control single; VCI denotes vector control integrated.



Figure 5: Average antigen prevalence (AgP) by intervention arm

Notes: MDA denotes mass drug administration; VCS denotes vector control single; VCI denotes vector control integrated.



It is made available under a CC-BY 4.0 International license .

856 Annex. Acronyms

It is made available under a CC-BY 4.0 International license .

- 899 Supporting information legends
- 900

901 S1 Figure. Discussion of study plans at the Field Unit. From left to right: Prof. Donald S.

- 902 Shepard, Dr B .K. Tyagi and Prof. Graham B. White
- 903
- 904 S2. Figure. Visit to a study village. From left to right: Shri R. Krishnamoorth (CRME
- Field Unit), Prof. Donald S. Shepard, Dr. Sunish Pulikkottil, Dr. Aung K. Lwin, Shri A.
- 906 Munirathinam (CRME Field Unit)